 -- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 GLOBE NEWSWIRE -- Chiasma, Inc. NASDAQ: CHMA, Chiasma or the Company, a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly, today announced that it will be presenting data from two Phase 3 clinical trials: the open-label extension of the CHIASMA OPTIMAL study and the MPOWEREDTM study, at the Endocrine Societys annual meeting, ENDO 2021. The conference will be held virtually from March 20-23, 2021. 